This morning, ATAI Life Sciences (Nasdaq: ATAI) experienced a shocking drop of nearly 40% in its stock price, plummeting to an all-time low since the company’s June 2021 Initial Public Offering. The cause? A failed lead asset from its majority-owned Perception Neuroscience unit.
To gain insight into the subtle distinctions between psilocybin and DMT, it is essential to explore their primary chemical similarities. Both belong to the tryptamine family, which encompasses naturally occurring neurotransmitters such as serotonin in addition to multiple psychedelic substances found in plants and fungi; yet there persists one noteworthy distinction: their metabolic properties.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.